The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 17, 2020

Filed:

Nov. 25, 2014
Applicant:

Bioscreening and Diagnostics Llc, Detroit, MI (US);

Inventors:

Ray O. Bahado-Singh, Gross Pointe Shores, MI (US);

Kypros Nicolaides, London, GB;

Assignee:

Bioscreening & Diagnostics LLC, Detroit, MI (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/00 (2006.01); A61B 5/055 (2006.01); A61B 5/00 (2006.01); G01N 33/68 (2006.01); G01R 33/465 (2006.01); A61B 8/08 (2006.01); G01R 33/46 (2006.01);
U.S. Cl.
CPC ...
A61B 5/055 (2013.01); A61B 5/4343 (2013.01); A61B 8/0866 (2013.01); G01N 33/6893 (2013.01); G01R 33/465 (2013.01); A61B 2503/045 (2013.01); G01N 2560/00 (2013.01); G01N 2800/32 (2013.01); G01N 2800/385 (2013.01); G01R 33/4625 (2013.01);
Abstract

Particular aspects of the invention are methods for assaying metabolite levels in samples from a patient during pregnancy using nuclear magnetic resonance and direct flow injection mass spectrometry. In various methods, the assayed metabolites may be acylcarnitine or one or more of C3-OH (hydroxypropionylcarnitine), C5-OH (C3DC), C10, C5:1-DC (glutaconylcarnitine), C14:1-OH (hydroxytetradecenoylcarnitine) and C14:2-OH. One or more methods also may include measuring nuchal translucency of the fetus. Other methods relate to predicting fetal congenital heart defects in a fetus.


Find Patent Forward Citations

Loading…